Cancer is becoming one of the defining healthcare challenges of the coming decades.
The International Agency for Research on Cancer (IARC) estimates that 20.6 million people were diagnosed with cancer in 2024, while approximately 9.8 million died from the disease. By 2050, annual new cancer cases are projected to reach 34.4 million, an increase of approximately 67%.
A growing global oncology burden
Annual new cancer cases worldwide · millions
Source: IARC / GLOBOCAN 2024. Includes non-melanoma skin cancer. Growth is calculated as (34.4 − 20.6) ÷ 20.6, rounded. The patterned bar represents a projection, not an observed outcome; both bars start at zero.
These figures represent more than an epidemiological challenge. They raise fundamental questions about healthcare capacity, access, investment priorities, and international collaboration.
Innovation is advancing. Access remains uneven.
Oncology has experienced substantial scientific progress, including advances in targeted therapies, immunotherapy, molecular diagnostics, and precision medicine. Yet scientific progress does not automatically translate into population-level impact.
The availability of diagnostic infrastructure, specialist capacity, treatment financing, and patient navigation varies substantially between health systems. A therapy may be clinically transformative and still have limited impact where patients cannot access timely diagnosis or appropriate care.
This creates a critical strategic challenge: how can healthcare innovation be deployed at scale, across different economic and healthcare environments?
Three strategic priorities
1. Move diagnosis earlier. Earlier detection can change treatment pathways and improve the potential for successful intervention in appropriate cancer types. Investment in diagnostics, pathology, molecular testing, and effective referral systems must therefore be considered alongside therapeutic innovation.
2. Design for access from the beginning. Market access should not be treated as a final commercial step. Reimbursement, infrastructure, clinical capacity, affordability, and regulatory pathways should inform development and international expansion strategies.
3. Build partnerships across the oncology ecosystem. Pharmaceutical companies, diagnostics manufacturers, hospitals, technology providers, governments, and investors each control different components of the patient journey. Strategic alliances can help connect these capabilities and address barriers that individual organizations cannot resolve independently.
The Global OneHealth view
The next generation of oncology leadership will require more than successful product launches. It will demand integrated strategies linking innovation, diagnostics, healthcare delivery, financing, and international market development.
For pharmaceutical and biotechnology companies, the opportunity lies in designing commercially sustainable approaches that also expand patient access. For diagnostics and medical technology businesses, it lies in becoming essential partners across the cancer care pathway. For investors and public institutions, it lies in supporting solutions that can be adapted to different health systems and deployed at meaningful scale.
Cancer’s growing burden makes one point clear: the future of oncology will be shaped not only by what science discovers, but by what healthcare systems can deliver.
Sources and reference links
Figures and context are drawn from the source above. Strategic interpretation and visuals are Global OneHealth editorial analysis.
The Global OneHealth View — From Insight to Action.
← All articles